Selected research
Industry Growth & Trends
Global Gene Therapy in CNS Disorder Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Gene Therapy in CNS Disorder market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Gene Therapy in CNS Disorder market include Novartis AG, Biogen, Voyager Therapeutics, Spark Therapeutics and Bluebird Bio Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Gene Therapy in CNS Disorder market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Gene Therapy in CNS Disorder market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gene Therapy in CNS Disorder market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gene Therapy in CNS Disorder.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Gene Therapy in CNS Disorder market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Gene Therapy in CNS Disorder Market by Company
Novartis AG
Biogen
Voyager Therapeutics
Spark Therapeutics
Bluebird Bio Inc.
Gene Therapy in CNS Disorder Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Gene Therapy in CNS Disorder Segment by Application
Parkinson's Disease
Huntington's Disease
Batten Disease
Alzheimer's Disease
Gene Therapy in CNS Disorder Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy in CNS Disorder market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy in CNS Disorder and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy in CNS Disorder.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Gene Therapy in CNS Disorder companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-viral Gene Therapy
Applications
- Parkinson's Disease
- Huntington's Disease
- Batten Disease
- Alzheimer's Disease
Companies covered
- Novartis AG
- Biogen
- Voyager Therapeutics
- Spark Therapeutics
- Bluebird Bio Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Gene Therapy in CNS Disorder Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Gene Therapy in CNS Disorder Market Size by Region (2021-2032)
- 1.4.1 Global Gene Therapy in CNS Disorder Market Size by Region (2021-2026)
- 1.4.2 Global Gene Therapy in CNS Disorder Market Size by Region (2027-2032)
- 1.5 Key Regions Gene Therapy in CNS Disorder Market Size (2021-2032)
- 1.5.1 North America Gene Therapy in CNS Disorder Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Gene Therapy in CNS Disorder Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size Growth Rate (2021-2032)
- 1.5.4 South America Gene Therapy in CNS Disorder Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Gene Therapy in CNS Disorder Market Size Growth Rate (2021-2032)
2 Gene Therapy in CNS Disorder Market by Type
- 2.1 Type Introduction
- 2.1.1 Viral Gene Therapy
- 2.1.2 Non-viral Gene Therapy
- 2.2 Global Gene Therapy in CNS Disorder Market Size by Type
- 2.2.1 Global Gene Therapy in CNS Disorder Market Size Overview by Type (2021-2032)
- 2.2.2 Global Gene Therapy in CNS Disorder Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Gene Therapy in CNS Disorder Market Size Forecasted by Type (2027-2032)
- 2.3 Global Gene Therapy in CNS Disorder Market Size by Regions
- 2.3.1 North America Gene Therapy in CNS Disorder Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Gene Therapy in CNS Disorder Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Gene Therapy in CNS Disorder Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Gene Therapy in CNS Disorder Market Size Breakdown by Type (2021-2026)
3 Gene Therapy in CNS Disorder Market by Application
- 3.1 Type Introduction
- 3.1.1 Parkinson's Disease
- 3.1.2 Huntington's Disease
- 3.1.3 Batten Disease
- 3.1.4 Alzheimer's Disease
- 3.2 Global Gene Therapy in CNS Disorder Market Size by Application
- 3.2.1 Global Gene Therapy in CNS Disorder Market Size Overview by Application (2021-2032)
- 3.2.2 Global Gene Therapy in CNS Disorder Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Gene Therapy in CNS Disorder Market Size Forecasted by Application (2027-2032)
- 3.3 Global Gene Therapy in CNS Disorder Market Size by Regions
- 3.3.1 North America Gene Therapy in CNS Disorder Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Gene Therapy in CNS Disorder Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Gene Therapy in CNS Disorder Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Gene Therapy in CNS Disorder Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Gene Therapy in CNS Disorder Industry Trends
- 4.2 Gene Therapy in CNS Disorder Industry Drivers
- 4.3 Gene Therapy in CNS Disorder Industry Opportunities and Challenges
- 4.4 Gene Therapy in CNS Disorder Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Gene Therapy in CNS Disorder Revenue (2021-2026)
- 5.2 Global Gene Therapy in CNS Disorder Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Gene Therapy in CNS Disorder Key Company Headquarters & Area Served
- 5.4 Global Gene Therapy in CNS Disorder Company, Product Type & Application
- 5.5 Global Gene Therapy in CNS Disorder Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Gene Therapy in CNS Disorder Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Gene Therapy in CNS Disorder Players Market Share by Revenue in 2025
- 5.6.3 2025 Gene Therapy in CNS Disorder Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Gene Therapy in CNS Disorder Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis AG Gene Therapy in CNS Disorder Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Biogen
- 6.2.1 Biogen Company Information
- 6.2.2 Biogen Business Overview
- 6.2.3 Biogen Gene Therapy in CNS Disorder Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Biogen Gene Therapy in CNS Disorder Product Portfolio
- 6.2.5 Biogen Recent Developments
- 6.3 Voyager Therapeutics
- 6.3.1 Voyager Therapeutics Company Information
- 6.3.2 Voyager Therapeutics Business Overview
- 6.3.3 Voyager Therapeutics Gene Therapy in CNS Disorder Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio
- 6.3.5 Voyager Therapeutics Recent Developments
- 6.4 Spark Therapeutics
- 6.4.1 Spark Therapeutics Company Information
- 6.4.2 Spark Therapeutics Business Overview
- 6.4.3 Spark Therapeutics Gene Therapy in CNS Disorder Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio
- 6.4.5 Spark Therapeutics Recent Developments
- 6.5 Bluebird Bio Inc.
- 6.5.1 Bluebird Bio Inc. Company Information
- 6.5.2 Bluebird Bio Inc. Business Overview
- 6.5.3 Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio
- 6.5.5 Bluebird Bio Inc. Recent Developments
7 North America
- 7.1 North America Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 7.3 North America Gene Therapy in CNS Disorder Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 8.3 Europe Gene Therapy in CNS Disorder Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 10.3 South America Gene Therapy in CNS Disorder Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Gene Therapy in CNS Disorder Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst